{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:33:54Z","timestamp":1771907634505,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1124\/dmd.112.050278","type":"journal-article","created":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T12:16:28Z","timestamp":1362226588000},"page":"933-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Which Metabolites Circulate?"],"prefix":"10.1016","volume":"41","author":[{"given":"Cho-Ming","family":"Loi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Dalvie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.050278_bib1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1067\/mcp.2001.114230","article-title":"Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation","volume":"69","author":"Abernethy","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2125.1999.00831.x","article-title":"Pharmacokinetics of flutamide in patients with renal insufficiency","volume":"47","author":"Anjum","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/tx7002273","article-title":"Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism","volume":"21","author":"Baillie","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.050278_bib4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/cr030440j","article-title":"Modeling kinetics of subcellular disposition of chemicals","volume":"109","author":"Balaz","year":"2009","journal-title":"Chem Rev"},{"key":"10.1124\/dmd.112.050278_bib5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0009-9236(97)90134-X","article-title":"Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate","volume":"61","author":"Borin","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib6","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1128\/AAC.41.9.1892","article-title":"Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients","volume":"41","author":"Borin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.112.050278_bib7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1989.159","article-title":"The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose","volume":"46","author":"Boyd","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.111.184721","article-title":"Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases","volume":"340","author":"Bratton","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.050278_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2125.2003.01785.x","article-title":"The pharmacokinetics of pioglitazone in patients with impaired renal function","volume":"55","author":"Budde","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0278-5846(98)00035-9","article-title":"Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients","volume":"22","author":"Chang","year":"1998","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1124\/dmd.112.050278_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0022-3565(25)12147-2","article-title":"Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds","volume":"275","author":"Chou","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.050278_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/j.1552-4604.1995.tb04097.x","article-title":"Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753\/MK 954) and its pharmacologically active metabolite EXP3174","volume":"35","author":"Christ","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0009-9236(98)90040-6","article-title":"10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes","volume":"63","author":"Dal\u00e9n","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib14","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1124\/dmd.108.023176","article-title":"Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans","volume":"36","author":"Dalvie","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/tx8004357","article-title":"Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites","volume":"22","author":"Dalvie","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.050278_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4172\/jbb.1000076","article-title":"Metabolism studies of desvenlafaxine","volume":"3","author":"DeMaio","year":"2011","journal-title":"J Bioequiv Availab"},{"key":"10.1124\/dmd.112.050278_bib17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/tx060203m","article-title":"A regulatory perspective on issues and approaches in characterizing human metabolites","volume":"19","author":"Davis-Bruno","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.050278_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-004-0762-z","article-title":"Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity","volume":"60","author":"Eap","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib19","doi-asserted-by":"crossref","first-page":"S 234","DOI":"10.1055\/s-2000-8525","article-title":"Clinical pharmacokinetics of pioglitazone","volume":"108 Suppl 2","author":"Eckland","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1124\/dmd.112.050278_bib20","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/0024-3205(79)90457-0","article-title":"Antischizophrenic drugs: differential plasma protein binding and therapeutic activity","volume":"24","author":"Freedberg","year":"1979","journal-title":"Life Sci"},{"key":"10.1124\/dmd.112.050278_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0091270005284193","article-title":"Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects","volume":"46","author":"Frohna","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1359-6446(05)03681-0","article-title":"Role of pharmacologically active metabolites in drug discovery and development","volume":"11","author":"Fura","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.112.050278_bib23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1139\/Y10-060","article-title":"Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes","volume":"88","author":"Hartman","year":"2010","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib25","first-page":"2220","article-title":"Excretion and metabolism of 14C-midazolam in humans following oral dosing","volume":"31","author":"Heizmann","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.112.050278_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2125.2003.01874.x","article-title":"Metabolism of citalopram enantiomers in CYP2C19\/CYP2D6 phenotyped panels of healthy Swedes","volume":"56","author":"Herrlin","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib27","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib28","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1124\/dmd.111.040931","article-title":"Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses","volume":"39","author":"Honkalammi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0163-7258(81)90056-5","article-title":"Drug metabolite kinetics","volume":"15","author":"Houston","year":"1982","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/00498259309057023","article-title":"Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man","volume":"23","author":"Howell","year":"1993","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.050278_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.clpt.6100311","article-title":"Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine","volume":"83","author":"Hynninen","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1021\/tx2005212","article-title":"Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies","volume":"25","author":"Isin","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.050278_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/tx800491e","article-title":"Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database","volume":"22","author":"Isoherranen","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.050278_bib34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/00498259009046817","article-title":"The metabolism of chlorpromazine N-oxide in man and dog","volume":"20","author":"Jaworski","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.050278_bib36","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1124\/dmd.110.034595","article-title":"Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans","volume":"38","author":"Kamel","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib37","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2125.2003.01988.x","article-title":"Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data","volume":"57","author":"Kerbusch","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/clpt.2009.145","article-title":"Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects","volume":"86","author":"Kim","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","article-title":"Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication","volume":"7","author":"Kirchheiner","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.112.050278_bib41","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/01.CIR.79.5.1068","article-title":"Stereoselective disposition and pharmacologic activity of propafenone enantiomers","volume":"79","author":"Kroemer","year":"1989","journal-title":"Circulation"},{"key":"10.1124\/dmd.112.050278_bib42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0090-9556(25)08020-1","article-title":"Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man","volume":"11","author":"Levy","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","article-title":"Role of pharmacokinetics and metabolism in drug discovery and development","volume":"49","author":"Lin","year":"1997","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.112.050278_bib44","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","article-title":"Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers","volume":"34","author":"Ling","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","article-title":"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans","volume":"58","author":"Lo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib46","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1517\/17425255.2010.497487","article-title":"Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters","volume":"6","author":"Lutz","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.112.050278_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/dmd.111.042200","article-title":"Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole","volume":"40","author":"Lutz","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00003088-199936040-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug","volume":"36","author":"Mahmood","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.112.050278_bib49","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1124\/mol.107.041459","article-title":"Involvement of multiple efflux transporters in hepatic disposition of fexofenadine","volume":"73","author":"Matsushima","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/clpt.2011.283","article-title":"Warfarin-amiodarone drug-drug interactions: determination of [I](u)\/K(I,u) for amiodarone and its plasma metabolites","volume":"91","author":"McDonald","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1128\/AAC.41.1.169","article-title":"Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection","volume":"41","author":"Morse","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.112.050278_bib52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00498254.2011.562330","article-title":"From definition to implementation: a cross-industry perspective of past, current and future MIST strategies","volume":"41","author":"Nedderman","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.050278_bib53","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1124\/dmd.108.020479","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds","volume":"36","author":"Obach","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0300-483X(99)00192-4","article-title":"Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions","volume":"144","author":"Oppermann","year":"2000","journal-title":"Toxicology"},{"key":"10.1124\/dmd.112.050278_bib55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y","article-title":"Serum protein binding of tolterodine and its major metabolites in humans and several animal species","volume":"20","author":"P\u00e5hlman","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.112.050278_bib56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/j.1552-4604.1998.tb04423.x","article-title":"Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects","volume":"38","author":"Patat","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1021\/tx300050f","article-title":"Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?","volume":"25","author":"Penner","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.050278_bib58","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/jps.20429","article-title":"The metabolic profile of azimilide in man: in vivo and in vitro evaluations","volume":"94","author":"Riley","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.112.050278_bib59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/clpt.1980.127","article-title":"A radioreceptor assay for propranolol and 4-hydroxypropranolol","volume":"28","author":"Rochester","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03602530600952172","article-title":"What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs","volume":"39","author":"Roffey","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.112.050278_bib62","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00228-005-0909-6","article-title":"The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor","volume":"61","author":"Sarapa","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/dmd.31.1.98","article-title":"Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism","volume":"31","author":"Sauer","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib64","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/00003088-200544060-00002","article-title":"Clinical pharmacokinetics of atomoxetine","volume":"44","author":"Sauer","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.112.050278_bib65","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.1998.00822.x","article-title":"Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance","volume":"46","author":"Schaber","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/00498254.2011.630110","article-title":"Why do metabolites circulate?","volume":"42","author":"Smith","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.050278_bib67","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2125.2002.01608.x","article-title":"Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole","volume":"53","author":"van Giersbergen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib68","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002280050667","article-title":"Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing","volume":"55","author":"van Heiningen","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s002130051039","article-title":"Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions","volume":"145","author":"von Moltke","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.112.050278_bib70","first-page":"631","article-title":"Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A","volume":"26","author":"Voorman","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-3565(24)37800-0","article-title":"Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A","volume":"287","author":"Voorman","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.050278_bib72","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0090-9556(24)15230-0","article-title":"Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects","volume":"27","author":"Weber","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050278_bib73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.1978.tb01655.x","article-title":"(+)-Propranolol clearance, an estimation of hepatic blood flow in man","volume":"5","author":"Weiss","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/clpt.2010.252","article-title":"Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency","volume":"89","author":"Yeung","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050278_bib75","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/BF00315316","article-title":"Pharmacokinetics of chlorpromazine and key metabolites","volume":"45","author":"Yeung","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050278_bib76","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/dmd.30.9.1013","article-title":"Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human","volume":"30","author":"Yuan","year":"2002","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.050278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:40:04Z","timestamp":1739907604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624115723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0090955624115723"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.050278","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which Metabolites Circulate?","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.050278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}